# Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/outcomes-to-first-line-pembrolizumab-in-patients-with-non-small-cell-lung-cancer/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Esther Aguilar,Biagio Ricciuti,Justin F. Gainor,Kenneth L. Kehl,Sasha Kravets,Suzanne E. Dahlberg,Mizuki Nishino,Lynette M. Sholl,Anika E. Adeni,S. Subegdjo,S. Khosrowjerdi,Rachel Peterson,Subba R. Digumarthy,C. Liu,Jennifer L. Sauter,Hira Rizvi,Kathryn C. Arbour,B.W. Carter,John V. Heymach,Mehmet Altan,Matthew D. Hellmann,Mark M. Awad |
| Citations | 339 |
| DOI | 10.1093/annonc/mdz288 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.1093/annonc/mdz288 |
| OpenAlex ID | https://openalex.org/W2969539132 |
| PMID | 31435660 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Matthew D. Hellmann](https://scholariq.org/researchers/matthew-d-hellmann/)
- [John V. Heymach](https://scholariq.org/researchers/john-v-heymach/)
- [Justin F. Gainor](https://scholariq.org/researchers/justin-f-gainor/)
- [Lynette M. Sholl](https://scholariq.org/researchers/lynette-m-sholl/)
- [Biagio Ricciuti](https://scholariq.org/researchers/biagio-ricciuti/)
- [Mizuki Nishino](https://scholariq.org/researchers/mizuki-nishino/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.